• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    4/9/24 12:31:26 PM ET
    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.0% to $10.16 during Tuesday's regular session. The market value of their outstanding shares is at $230.0 million.
    • BioSig Technologies (NASDAQ:BSGM) stock increased by 27.41% to $1.58. The market value of their outstanding shares is at $14.7 million.
    • Syros Pharmaceuticals (NASDAQ:SYRS) shares moved upwards by 24.44% to $5.6. The market value of their outstanding shares is at $148.1 million.
    • Inspire Veterinary (NASDAQ:IVP) shares increased by 19.13% to $0.06. The company's market cap stands at $1.7 million. As per the news, the Q4 earnings report came out yesterday.
    • Addex Therapeutics (NASDAQ:ADXN) shares moved upwards by 16.5% to $25.46. The market value of their outstanding shares is at $26.9 million.
    • Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.89% to $15.99. The market value of their outstanding shares is at $786.1 million.

    Losers

    • Vincerx Pharma (NASDAQ:VINC) shares decreased by 74.6% to $1.22 during Tuesday's regular session. The company's market cap stands at $26.0 million.
    • Tilray Brands (NASDAQ:TLRY) shares decreased by 19.5% to $2.08. The company's market cap stands at $1.5 billion. The company's, Q3 earnings came out today.
    • Kineta (NASDAQ:KA) shares fell 19.25% to $0.44. The market value of their outstanding shares is at $4.7 million.
    • Cadrenal Therapeutics (NASDAQ:CVKD) shares declined by 17.65% to $0.42. The company's market cap stands at $6.7 million.
    • Candel Therapeutics (NASDAQ:CADL) shares fell 15.56% to $5.43. The company's market cap stands at $159.3 million.
    • Acorda Therapeutics (NASDAQ:ACOR) stock fell 15.42% to $1.01. The company's market cap stands at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ACRV
    $ADXN
    $BSGM

    CompanyDatePrice TargetRatingAnalyst
    Tilray Brands Inc.
    $TLRY
    1/27/2026Hold
    Canaccord Genuity
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Nurix Therapeutics Inc.
    $NRIX
    11/24/2025$30.00Buy
    Truist
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Nurix Therapeutics Inc.
    $NRIX
    10/21/2025$24.00Outperform
    Mizuho
    Candel Therapeutics Inc.
    $CADL
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    Candel Therapeutics Inc.
    $CADL
    6/30/2025$23.00Buy
    H.C. Wainwright
    Acrivon Therapeutics Inc.
    $ACRV
    5/5/2025$6.00Overweight
    Piper Sandler
    More analyst ratings

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need subtype responsible for ~50% of EC mortality Initiated Arm 3 (ACR-368 + ultra low-dose gemcitabine) and adding Arm 4 (ACR-368) Phase 2b cohorts in all-comer (biopsy-independent) serous EC subjects Initial Phase 1 ACR-2316 data in AP3-prioritized solid tumor types showed favorable tolerability and promising clinical activity, notably in heavily pre-treated lung cancer subjects Cash, cash equivale

    3/19/26 7:21:18 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia

    NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical's long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products. Tilray Medical has operated in Australia for several years, supplying EU‑GMP certified medical cannabis through established prescriber, pharmacy, and clinical distribution channels. This latest expansion represents a scal

    3/19/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Breckenridge Distillery Expands Its Colorado Presence with Cheba Hut Partnership

    BRECKENRIDGE, Colo., March 18, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY is excited to announce that Cheba Hut 'Toasted' Subs will roll out Breckenridge Distillery products across 18 Colorado-based Cheba Hut restaurants. This will bring Breckenridge Distillery's award-winning Bourbon Whiskey to all participating locations, with select restaurants in Boulder, Dillon, and one Denver location also pouring Mountain Shot, the distillery's bold, shootable chocolate and mint whiskey. Rooted in a shared love for mountain culture, irreverent fun, and doing things the Colorado way, fans wil

    3/18/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    SEC Filings

    View All

    SEC Form S-8 filed by Acrivon Therapeutics Inc.

    S-8 - Acrivon Therapeutics, Inc. (0001781174) (Filer)

    3/19/26 7:41:45 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acrivon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)

    3/19/26 7:21:17 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Acrivon Therapeutics Inc.

    10-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)

    3/19/26 7:10:31 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Blume-Jensen Peter bought $82,124 worth of shares (49,000 units at $1.68) (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:02:48 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Levy Adam D. bought $14,999 worth of shares (8,832 units at $1.70), increasing direct ownership by 73% to 20,983 units (SEC Form 4)

    4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)

    1/16/26 4:01:38 PM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Dyer Timothy Mark

    3 - Addex Therapeutics Ltd. (0001574232) (Issuer)

    3/18/26 11:07:06 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Nunn Jason Raleigh

    3 - Addex Therapeutics Ltd. (0001574232) (Issuer)

    3/18/26 11:06:44 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Manke Isaac

    3 - Addex Therapeutics Ltd. (0001574232) (Issuer)

    3/18/26 11:06:22 AM ET
    $ADXN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Tilray

    Canaccord Genuity initiated coverage of Tilray with a rating of Hold

    1/27/26 9:29:20 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Nurix Therapeutics with a new price target

    Truist resumed coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $30.00

    11/24/25 9:17:24 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Leadership Updates

    Live Leadership Updates

    View All

    Breckenridge Distillery Appoints Romano Beverage for Distribution in Illinois

    BRECKENRIDGE, Colo., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand owned by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), has announced appointment of Romano Beverage, a respected partner, to manage distribution responsibilities within the state. Romano Beverage, a trusted leader in beverage distribution, is now overseeing Breckenridge Distillery's full spirits collection across Illinois—including its celebrated bourbon whiskey, whiskey, rum, vodka, gin, and newly launched Mountain Shot. Romano's strong presence in Illinois and dedication to exceptional service make them the perfect partner to help Breckenridge Distillery thr

    2/4/26 8:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

    SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

    11/14/24 5:28:08 PM ET
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ACRV
    $ADXN
    $BSGM
    Financials

    Live finance-specific insights

    View All

    Tilray Brands Acquires BrewDog Australia, Establishing Strategic Base to Accelerate Global Beverage and Consumer Products Growth Across the Asia-Pacific Region

    Acquisition Includes BrewDog's Profitable Australian Operations Including Brisbane Brewery and Two Flagship Bars Transaction Positions Tilray to Scale BrewDog Across Australia's National Retail and Grocery Channels and Introduce Broader Beverage Portfolio Across Asia-Pacific NEW YORK and BRISBANE, Australia, March 09, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced the completion of the acquisition of BrewDog Brewing Australia Pty Ltd., including BrewDog's Australian brewing and pr

    3/9/26 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

    Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs  Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027 Tilray's Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1 Conference Call Scheduled for 12:30pm ET NEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly strategic

    3/2/26 10:17:01 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

    Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low d

    1/8/26 7:30:00 AM ET
    $ACRV
    Biotechnology: Pharmaceutical Preparations
    Health Care